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and it concluded in April 2012. Socioeconomic costs per patient were calculated.
Costs were divided in 4 categories: direct health care costs (drugs, medical visits,
exams, material), direct non-health care formal costs (professional carers, social
services), direct non-health care informal costs (unpaid carers) and indirect costs
(patient’s and carer’s productivity loss). Both patients and their carers completed a
generic scale EQ-5D to measure HRQOL. RESULTS: A total of 697 patients and their
carers responded the questionnaire, 28% affected by Cystic Fibrosis, 21% by Sclero-
derma and 11% by X-Fragile Syndrome. For most of the diseases an important part
of the total costs were the direct non-health care informal costs, i.e. time of pa-
tient’s main carer and other unpaid carers. Total annual cost per patient oscillated
between 20.000 € (Haemophilia) and 200.000 € (Mucopolysaccharidosis). Regarding
the HRQOL measured by EQ-5D, the most affected patients were those with Muco-
polysaccharidosis and Duchenne Muscular Distrophy, which correlated with the
HRQOL of their carers and total costs. CONCLUSIONS: Besides results on costs and
HRQOL presented, the main outcome of BURQOL-RD is an integrated and harmo-
nized set of instruments to assess and monitor socio-economic burden and HRQOL
of patients affected by rare diseases and their carers. The tools developed by
BURQOL-RD will also improve RD awareness and literacy among European citizens.
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OBJECTIVES: To explore the impact of neuropathic pain component on quality of
life in patients with severe, chronic low back pain. METHODS: A phase 3b study
was performed, including a total of 208 patients with severe, chronic low back pain
who had been inadequately managed with World Health Organization Step I or II
analgesics or had no regular analgesic treatment and were switched to tapentadol
prolonged release. The likelihood of a neuropathic pain component (NPC) was
determined using the painDETECT questionnaire: negative (score 0-12), unclear
(score 13-18), or positive (score 19-38). The painDETECT questionnaire was previ-
ously shown to have high sensitivity, specificity and positive predictive accuracy.
RESULTS: Mean pain intensity at baseline, measured with 11-point numerical rat-
ing scale, was slightly higher in patients with painDETECT positive score (7.6) than
in patients with painDETECT unclear (7.3) and patients with painDETECT negative
(7.1) score. However, patients with painDETECT positive score had the mean EQ-5D
value substantially lower (0.31) than patients with pure nociceptive pain (0.44).
Similarly, lower scores were detected in all dimensions of the SF-36 when NPC was
present, especially in social functioning, role-physical, role-emotional, and mental
health. Scores with the Hospital Anxiety and Depression Scale were worse for both
dimensions if NPC was present. Whereas 12% of patients with pure nociceptive
pain rated their overall quality of sleep as poor, there were 27% in patients with
painDETECT positive subset. Moreover, in pre-study period, patients in the pain-
DETECT positive subset consulted a doctor earlier and more frequently, visited
more doctors because of their pain, changed more analgesic regimens since pain
started, and were more absent from work than patients in the painDETECT nega-
tive subset. CONCLUSIONS: The presence of a neuropathic pain component ap-
pears to have a substantial detrimental impact on quality of life in patients with
severe, chronic low back pain.
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THE RELATIONSHIP BETWEEN PAIN SEVERITY AND HEALTH UTILITIES:
INFORMING CLINICAL TRIAL DESIGN TO SUBSTANTIATE VALUE
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OBJECTIVES: Achieving market access requires substantiating incremental value
for the indicated patient population. The aim of this project was to provide an
example of how mapping the relationship between clinical states and health util-
ities can inform early development strategy and clinical trial inclusion criteria.
METHODS: US 2011 National Health and Wellness Survey data were used. Respon-
dents with pain in the past month were included. General linear models were used
to examine the relationship between pain level in the last week (0 to 10 scale) and
health utilities (using the SF6D algorithm) while controlling for sociodemographics
and health history. Models were replicated within pain subgroups (e.g., neuro-
pathic pain, nocioceptive pain etc).RESULTS:A total of 24,778 respondents (33.04%)
reported pain in the past month (mean age 50.24; 51.71% were female). The range
of health utilities was 0.35-1.00. Pain level was significantly associated with health
utilities (b-0.025, p.05), though a cubic relationship was also identified whereby
a 1-point reduction in pain was associated with a greater increase in utilities
among those with mild pain (e.g., a reduction from 1 to 0 on the pain scale led to
0.027 increase in utilities) compared with those with severe pain (reduction from 10
to 9 lead to 0.010 increase in utilities). Subgroups were also investigated; for exam-
ple, only a significant linear relationship (no higher order trends) between pain
level and health utilities was observed among those with neuropathic pain (b-
0.27, p.05). CONCLUSIONS: The overall relationship between the level of pain and
health utilities was non-linear suggesting that more incremental value could be substan-
tiated by reducing milder pain than more severe pain. However, not all subgroups fol-
lowed this pattern emphasizing the benefits of understanding the relationship between
estimated treatment effects and health utilities early in the developmental process to
inform clinical trial design, optimize incremental value, and drive cost effectiveness.
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OBJECTIVES: In January 2012, the protease inhibitors boceprevir and telaprevir
were found to be cost effective in the Irish setting. The complexity of the treatment
regimens, the high cost of the agents and the potential for increased patient mor-
bidity prompted interested clinical specialist groups and health care service pro-
viders to collaborate in the establishment of an outcomes registry for Hepatitis C
patients. The goal of the network was to optimise the quality of care of patients
with hepatitis C (HCV) treated with directly acting antiviral therapy (DAA). The aim
is to describe the process of development of a national outcomes treatment registry
under the auspices of the Irish Hepatitis C Outcomes Registry Network (ICORN).
METHODS: The review took into account the challenges and considerations for the
design, development and implementation of the registry. Identified issues in the
development phase included governance, stakeholder involvement, feasibility,
funding, analysis and ethics and privacy. Those identified in the design phase
included the study design, outcomes and research questions. The implementation
phase will involve training and education, data capture, database management,
monitoring, reporting systems and research. RESULTS: The Executive Committee
was established in the first instance, with the subsequent appointment of a clinical
advisory group sub-committee to develop clinical guidelines and treatment proto-
cols. The outcomes required of the registry were ratified. Seven centres of excel-
lence were identified for data collection. A data capture tool was designed in col-
laboration with software expertise. Data protection considerations were put in
place. A clear reporting structure for funding for the registry was established.
CONCLUSIONS:Observational data generated through the registry allows real time
monitoring of safety, effectiveness and cost effectiveness of triple therapy regimes
in HCV. This project is a reference case in Ireland for extension of health technol-
ogy assessment beyond the reimbursement decision.
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OBJECTIVES: To describe treatment changes following the initiation of a non-bio-
logic DMARD in PsA patients. METHODS: Adult patients with  2 PsA diagnoses
(from office visits) with continuous insurance coverage  6-month before and 
12-month post-index date (i.e., first prescription of a non-biologic DMARD) were
selected from the MarketScan Commercial Claims database (2005-2009). Patients
who used a biologic/non-biologic DMARDs or had a diagnosis of ankylosing spon-
dylitis before the index date were excluded. Treatment discontinuation was de-
fined as a treatment interruption 60 consecutive days. Therapy modification was
defined as a switch (initiation of a biologic/non-biologic DMARD [not used at the
index date] within 60 days of the index biologic discontinuation date) or a therapy
augmentation (use of a non-biologic/biologic DMARD [not used at the index date]
concomitantly with the index non-biologic DMARD for 28 consecutive days). The
12-month therapy modification, switch, and augmentation rates were reported.
RESULTS: A total of 1,698 PsA patients met the selection criteria; 71.7% initiated on
methotrexate, 17.5% on sulfasalazine. Over the 12-month study period, 72.5% of the
patients had 1 therapy change (median time: 86 days). More specifically, 57.7% of
patients discontinued the index non-biologic DMARD, 13.1% switched to a biologic
DMARD, 9.3% switched to another non-biologic DMARD, 21.4% had a therapy augmen-
tation with a biologic DMARD and 7.4% had a therapy augmentation with another
non-biologic DMARD. Among patients who initiated a biologic during the study period
(N513), 90.8% did not use other oral DMARDs, while 9.2% also initiated a second oral
DMARD either in combination or sequentially. CONCLUSIONS: This study suggests
that PsA patients newly initiated on a non-biologic DMARD do not remain on the index
therapy for a long period of time. Most patients switched to or added on biologics
quickly without using a second oral DMARD.
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THE EFFECT OF POSITIONING AND PNF-EXERCISE TO POSTOPERATIVE
BLEEDING AFTER HIP REPLACEMENT
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OBJECTIVES: Postoperative positioning has beneficial effects on postoperative
blood-saving, HGB and HTC reduction after knee replacement, and reduces the
complications of transfusion. METHODS: Total of 96 people with hip replacement
(age 6920) were included in 4 groups who were treated on Orthopaedic Depart-
ment in Zala County Hospital in 2012. I.a.group: traditional way of physiotherapy
following the hospital protocol (not upraised lower limb) I.b.group: the same to I.a.,
supplemented with one special exercise from PNF-method (irradiation, effecting
the operated side; repeat it 5-15 times/hour during the first 3 day) II.a.group: placed
the lower limb in 30° hip and knee flexion  traditional physiotherapy, II.b.group:
same to II.a, supplemented with the special PNF exercise. The postoperative blood
volume (after 6, 24, 48, 72 hours) and HGB, HTC (pre- and postop.24h) were mea-
sured. Data were analysed by Wilcoxon-tests applying SPSS statistic software.
RESULTS: The 30°hip and knee flexion increased the postoperative bleeding
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